tetano
Editor, Senior Moderator
J Gen Virol. 2014 Aug 28. pii: vir.0.067736-0. doi: 10.1099/vir.0.067736-0. [Epub ahead of print]
Infection of influenza virus NA vaccinated mice with homologous influenza virus leads to strong protection against heterologous influenza viruses.
He B1, Chang H1, Liu Z1, Huang C1, Liu X2, Zheng D2, Fang F1, Sun B3, Chen Z4.
Author information
Abstract
Vaccination is the best measure to prevent influenza pandemics. Here we studied the protective effect against heterologous influenza viruses, including A/reassortant/NYMC X-179A (pH1N1), A/chicken/Henan/12/2004 (H5N1), A/Chicken/Jiangsu/7/2002 (H9N2) and A/Guizhou/54/89xA/PR/8/34 (A/Guizhou-X) (H3N2), in mice first vaccinated with a DNA vaccine of hemagglutinin (HA) or neuraminidase (NA) of A/PR/8/34 (PR8) and then infected with the homologous virus. We showed that PR8 HA or NA vaccination both protected mice against a lethal dose of the homologous virus; PR8 HA or NA vaccination and then PR8 infection in mice respectively offered poor or excellent protection against a second, heterologous influenza virus challenge. In addition,before the second heterologous influenza infection, the highest antibody level against the NP, M1 and M2 was found in PR8 NA DNA vaccinated and PR8 infected group. The level of induced cellular immunity against NP and M1 showed a trend consistent with that seen in antibody levels. However,PR8HA+NA and then PR8 infection resulted in limited protection against heterologous influenza virus challenges. Results of the present study demonstrated that infection of the homologous influenza virus in mice already immunized with a NA vaccine could provide excellent protection against subsequent infection of a heterologous influenza virus. These findings suggest that NA, a major antigen of influenza virus, could be an important candidate antigen for universal influenza vaccines.
Copyright ? 2014, the Society for General Microbiology.
KEYWORDS:
cross protection; hemagglutinin; influenza; neuraminidase
PMID:
25170051
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25170051
Infection of influenza virus NA vaccinated mice with homologous influenza virus leads to strong protection against heterologous influenza viruses.
He B1, Chang H1, Liu Z1, Huang C1, Liu X2, Zheng D2, Fang F1, Sun B3, Chen Z4.
Author information
Abstract
Vaccination is the best measure to prevent influenza pandemics. Here we studied the protective effect against heterologous influenza viruses, including A/reassortant/NYMC X-179A (pH1N1), A/chicken/Henan/12/2004 (H5N1), A/Chicken/Jiangsu/7/2002 (H9N2) and A/Guizhou/54/89xA/PR/8/34 (A/Guizhou-X) (H3N2), in mice first vaccinated with a DNA vaccine of hemagglutinin (HA) or neuraminidase (NA) of A/PR/8/34 (PR8) and then infected with the homologous virus. We showed that PR8 HA or NA vaccination both protected mice against a lethal dose of the homologous virus; PR8 HA or NA vaccination and then PR8 infection in mice respectively offered poor or excellent protection against a second, heterologous influenza virus challenge. In addition,before the second heterologous influenza infection, the highest antibody level against the NP, M1 and M2 was found in PR8 NA DNA vaccinated and PR8 infected group. The level of induced cellular immunity against NP and M1 showed a trend consistent with that seen in antibody levels. However,PR8HA+NA and then PR8 infection resulted in limited protection against heterologous influenza virus challenges. Results of the present study demonstrated that infection of the homologous influenza virus in mice already immunized with a NA vaccine could provide excellent protection against subsequent infection of a heterologous influenza virus. These findings suggest that NA, a major antigen of influenza virus, could be an important candidate antigen for universal influenza vaccines.
Copyright ? 2014, the Society for General Microbiology.
KEYWORDS:
cross protection; hemagglutinin; influenza; neuraminidase
PMID:
25170051
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25170051